Advances in Hyperkalemia Management: Implications for Patients and Providers
Credit(s): 0.25 (15 min)
11/13/2020 - 1:00 - 2:00 PM ET
Conventional treatment of hyperkalemia is restricted by adverse events, as well as a dearth of evidence supporting clinical use (specifically with sodium polystyrene sulfonate). For medication-induced hyperkalemia, treatment involves a dose decrease or discontinuation of the offending agent (usually a renin-angiotensin-aldosterone system inhibitor [RAASI]); however, this often prevents patients from receiving appropriate guideline-directed management. Recent research has led to the development of two novel potassium binders with good safety profiles that allow patients to maintain or increase the use of RAASIs for cardio- and reno-protection.
This CME activity, Advances in Hyperkalemia Management: Implications for Patients and Providers, will help participating clinicians identify those patient populations most likely to present with or develop hyperkalemia, and utilize the appropriate conventional and/or novel agents to correct subacute hyperkalemia.
Welcome and Introductions
Understanding the Current Subacute/Chronic Hyperkalemia Armamentarium
Improving the Care of Adults with and at Risk for Hyperkalemia
Q&A Session and Activity Roundup
This activity is intended for physicians, hospitalists, nephrologists, and cardiologists involved in the management and education of adults with or at risk for hyperkalemia.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
Compare and contrast safety and efficacy data on novel and conventional agents for correcting subacute/chronic hyperkalemia
Identify patient populations likely to present with or develop hyperkalemia
Incorporate novel agents for correcting subacute hyperkalemia into patient care plans
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedChi, The Maryland State Medical Society, and Rockpointe. MedChi is accredited by the ACCME to provide continuing medical education for physicians.
MedChi designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email firstname.lastname@example.org.
ABIM MOC DESIGNATION STATEMENT Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through MedChi’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
Alpesh Amin, MD, MBA, MACP, SFHM, FACC, FRCP (Lond)
Thomas and Mary Cesario Endowed Chair, Department of Medicine
Professor of Medicine, Business, Public Health, Nursing Science, & Biomedical Engineering
Executive Director, Hospitalist Program
University of California, Irvine
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CE CREDIT
There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 66% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.
Jointly provided by MedChi and Rockpointe
This program is supported by an unrestricted educational grant from AstraZeneca.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
A.C.T. N.O.W.: A Challenge To Neurologists to Open the Window-of-Opportunity for Patients with Early Alzheimer’s Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.